Dr. Lal Path Labs Ltd.LALPATHLABCorporate

Healthcare Diagnostics & Research Latest results: Jun 2026 15 quarters of data

₹1,859.90

MCap ₹31,056 Cr · P/E 56.9

Dr. Lal Path Labs Ltd. — Stock analysis & AI research Dr. Lal Path Labs Ltd. — Seasonality — best & worst months Dr. Lal Path Labs Ltd. — Technical indicators & charts Dr. Lal Path Labs Ltd. — Technical setup — score, trend, support & resistance Dr. Lal Path Labs Ltd. — Ascending Channel pattern forming Dr. Lal Path Labs Ltd. — Live exchange announcements

📋 High ROE Stocks 📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 High Profit Growth Stocks 📋 Low Debt Stocks 📈 Bollinger Squeeze Stocks 🏭 Healthcare sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹798 Cr

Sales · Jun 2026

+19.1% YoY

₹248 Cr

Operating Profit · Jun 2026

+28.9% YoY

31.0%

OPM % · Jun 2026

+8.0% YoY

₹170 Cr

Net Profit · Jun 2026

+27.2% YoY

₹10.15

EPS · Jun 2026

-35.8% YoY

📝 Dr. Lal Path Labs Ltd. — results explained

Quarter ended June 2026 (Q1 FY27)

Dr. Lal Path Labs Ltd. reported revenue of ₹798 crore for the quarter ended June 2026 (Q1 FY27), up 19.1% from ₹670 crore in the same quarter last year, and up 13.5% sequentially over the March 2026 quarter.

Net profit rose 27.2% year-on-year to ₹170 crore, from ₹134 crore. Earnings per share (EPS) came in at ₹10.15.

Operating profit stood at ₹248 crore — an operating margin (OPM) of 31.0%, compared with 28.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Dr. Lal Path Labs Ltd. posted revenue of ₹2,764 crore, a growth of 12.3% over FY25, with a net profit of ₹509 crore (up 3.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,892 crore with a net profit of ₹546 crore.

Valuation snapshot

At the current price of ₹1,859.90, LALPATHLAB has a market capitalisation of ₹31,056 crore and a trailing P/E of about 56.9.

Within the Diagnostics & Research industry, it is the 2nd-largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 52.93%, foreign institutional investors (FIIs) 18.73%, domestic institutional investors (DIIs) 21.58%, public shareholders 6.35% of Dr. Lal Path Labs Ltd..

Promoter holding slipped from 53.19% to 52.93% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹31,056 Cr

Current Price ?

₹1,859.9

P/E ?

56.93below ind

Industry P/E ?

70.20

P/B ?

12.38

P/S ?

10.74

P/FCF ?

67.08

Enterprise Value ?

₹31,255 Cr

EV/EBITDA ?

37.32

PEG ?

1.90

Earnings Yield ?

2.1%

Dividend Yield ?

0.77%

Profitability & Returns

Sales (TTM) ?

₹2,892 Cr

OPM ?

29.0%

Profit after tax (TTM) ?

₹546 Cr

EPS (TTM) ?

₹32.67

ROCE ?

28.0%

ROE ?

21.7%

ROA ?

17.3%

Growth

Sales — latest qtr ?

₹798 Cr

PAT — latest qtr ?

₹170 Cr

YoY qtr sales growth ?

19.1%

YoY qtr profit growth ?

27.2%

Sales growth (3y) ?

11%

Sales growth (5y) ?

12%

Profit growth (3y) ?

30%

Profit growth (5y) ?

13%

Financial Health

Debt ?

₹199 Cr

Debt to Equity ?

0.08

Interest Coverage ?

27.0

Current Ratio ?

N/A

Ownership

Promoter holding ?

52.93%

Change in promoter holding ?

-0.86%

Pledged percentage ?

N/A

Market

Return 3 months ?

10.2%

Return 6 months ?

32.7%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	489	491	541	601	539	545	602	660	597	603	670	731	660	703	798	+19.1%	+13.5%
Operating Profit	113	116	146	178	141	145	170	202	154	169	192	224	179	187	248	+28.9%	+32.4%
Other Income	10	14	14	18	18	18	21	22	25	26	28	25	-6	24	32	+13.9%	+32.9%
Interest	9	9	8	8	7	7	6	6	5	5	5	5	7	6	6	+26.0%	+5.0%
Depreciation	38	38	35	36	36	37	35	35	36	36	35	40	42	45	44	+26.9%	-1.3%
Profit Before Tax	76	83	118	152	116	120	150	183	138	153	181	204	124	160	229	+26.4%	+42.9%
Net Profit	54	57	84	111	82	86	108	131	98	156	134	152	91	132	170	+27.2%	+29.2%
EPS	6.33	6.84	9.95	13.09	9.74	10.13	12.79	15.52	11.57	18.57	15.80	17.95	5.40	7.84	10.15	-35.8%	+29.5%
OPM %	23.1%	23.5%	27.0%	29.6%	26.2%	26.5%	28.2%	30.7%	25.8%	28.0%	28.7%	30.6%	27.1%	26.6%	31.0%	+8.0%	+16.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹2,462 Cr	₹2,764 Cr	₹2,892 Cr	+12.3%
Operating Profit	₹696 Cr	₹782 Cr	₹838 Cr	+12.4%
OPM %	28.25%	28.29%	28.96%	+0.1%
NPM %	19.99%	18.42%	18.86%	-7.9%
Other Income	₹93 Cr	₹71 Cr	₹75 Cr	-23.9%
Depreciation	₹142 Cr	₹162 Cr	₹171 Cr	+13.8%
Interest	₹22 Cr	₹23 Cr	₹24 Cr	+4.5%
EBIT	₹553 Cr	₹620 Cr	₹666 Cr	+12.1%
PBT	₹624 Cr	₹669 Cr	₹717 Cr	+7.1%
Tax	₹92 Cr	—	₹58 Cr	—
Net Profit	₹492 Cr	₹509 Cr	₹546 Cr	+3.4%
EPS	₹58.45	₹46.99	₹41.34	-19.6%
Material Cost	₹364 Cr	—	₹152 Cr	—
Employee Cost	₹356 Cr	—	₹133 Cr	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	83	83	84	168	+100.0%
Reserves	1,583	1,766	2,089	2,341	+12.1%
Borrowings	420	247	157	199	+26.8%
Other Liabilities	297	357	383	439	+14.6%
Total Liabilities	2,383	2,454	2,713	3,146	+16.0%
Fixed Assets	1,305	1,228	1,168	1,257	+7.6%
CWIP	5	6	3	6	+100.0%
Investments	150	114	327	423	+29.4%
Other Assets	923	1,107	1,215	1,461	+20.2%
Total Assets	2,383	2,454	2,713	3,146	+16.0%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	456	535	569	636	+11.8%
Cash from Investing Activity	-287	-24	-303	-422	-39.3%
Cash from Financing Activity	-283	-414	-334	-264	+21.0%
Net Cash Flow	-114	97	-68	-50	+26.5%
Free Cash Flow	412	479	516	463	-10.3%
CFO/OP	115%	110%	105%	104%	-1.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	13	13	13	15	+15.4%
Inventory Days	28	30	27	30	+11.1%
Days Payable	127	151	151	123	-18.5%
Cash Conversion Cycle	-87	-108	-110	-79	+28.2%
Working Capital Days	-56	-46	-30	27	+190.0%
ROCE %	18%	25%	29%	28%	-3.4%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	53.79%	53.21%	53.21%	53.21%	53.19%	52.93%	-0.5%
FIIs	21.69%	21.86%	20.29%	17.18%	17.36%	18.73%	+7.9%
DIIs	17.62%	18.22%	19.20%	21.37%	21.59%	21.58%	-0.0%
Government	0.29%	0.27%	0.01%	0.01%	0.01%	—	—
Public	6.22%	6.07%	6.94%	7.88%	7.47%	6.35%	-15.0%
Others	0.39%	0.37%	0.35%	0.34%	—	—	—
No. of Shareholders	1,18,656	1,12,703	1,16,167	1,14,527	1,11,037	1,13,559	+2.3%

⚖️ Peer comparison

Industry: Diagnostics & Research · 3 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SAILIFE SAI LIFE	₹1,585.00	33,664	95.7	2,181	343	29.0%	15.7%	29.4%	105.3%	3.8%	18.2%
2	LALPATHLAB Dr. Lal	₹1,897.00	31,676	58.5	2,892	546	29.0%	18.9%	12.3%	3.4%	19.1%	27.2%
3	SYNGENE Syngene International	₹383.10	15,420	69.8	3,600	221	22.3%	6.1%	2.6%	-36.2%	-15.8%	-110.4%

❓ Frequently asked questions

What was Dr. Lal Path Labs Ltd.'s revenue in Q1 FY27?

What was Dr. Lal Path Labs Ltd.'s net profit in Q1 FY27?